Drug intelligence / Profile preview

meningococcal polysaccharide + diphtheria toxoid

Development stage: Unknown
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

A quadrivalent conjugate vaccine containing purified capsular polysaccharide antigens from Neisseria meningitidis serogroups A, C, Y, and W-135, each conjugated to diphtheria toxoid protein. It induces active immunity by stimulating the production of specific IgG, IgM, and IgA antibodies against these meningococcal serotypes through T-cell dependent responses conferred by the protein carrier. It is primarily used for the prevention of invasive meningococcal disease in individuals 9 months through 55 years of age[1][2][4].

Brand names: Menactra
Other names: meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine

Targets

Neuraminidase

Beyond the preview

Go deeper on meningococcal polysaccharide + diphtheria toxoid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on meningococcal polysaccharide + diphtheria toxoid.

Explore the full profile